TABLE I.
Baseline characteristics of the study patients
| Variable |
Neutropenia
|
p Value | ||
|---|---|---|---|---|
|
Yes
|
Yes
|
No
|
||
| g-csf | No g-csf | No g-csf | ||
| Patients (n) | 18 | 44 | 31 | |
| Mean age (years) | 62 (13) | 62 (13) | 60 (14) | 0.77 |
| Sex [n (%)] | ||||
| Men | 8 (44.4) | 26 (59.1) | 19 (61.3) | 0.48 |
| Women | 10 (55.6) | 18 (40.9) | 12 (38.7) | |
| Smoking history [n (%)] | 3 (16.7) | 17 (38.6) | 12 (38.7) | 0.21 |
| Positive family history [n (%)] | 3 (16.7) | 18 (40.9) | 13 (41.9) | 0.15 |
| Household income, 2006 ($) | ||||
| Median | 84,858 | 71,448 | 80,545 | 0.12 |
| Standard deviation | 20,874 | 25,545 | 28,231 | |
| Comorbidities | ||||
| Heart failure | 0 | 1 (2.3) | 0 | 1.00 |
| Lung disease | 1 (5.6) | 0 | 0 | 0.19 |
| Renal impairment | 2 (11.1) | 3 (6.8) | 1 (3.2) | 0.48 |
| Hepatic dysfunction | 0 | 1 (2.3) | 1 (3.2) | 1.00 |
| Diabetes | 4 (22.2) | 11 (25.0) | 3 (9.7) | 0.24 |
| Coronary artery disease | 0 | 5 (11.4) | 1 (3.2) | 0.17 |
| Gastroesophageal reflux disease | 0 | 1 (2.3) | 0 | 0.57 |
| Hypothyroidism | 0 | 3 (6.8) | 1 (3.2) | 0.67 |
| Atrial fibrillation | 0 | 2 (4.5) | 2 (6.5) | 0.56 |
| Venous thromboembolism | 1 (5.6) | 2 (4.5) | 6 (19.4) | 0.19 |
| Inflammatory bowel disease | 1 (5.6) | 2 (4.5) | 5 (16.1) | 0.17 |
| cci–age score > 10 | 2 (11.1) | 6 (13.6) | 4 (12.9) | 1.00 |
| ecog performance status | ||||
| 0 | 8 (44.4) | 17 (38.6) | 17 (54.8) | 0.38 |
| 1–3 | 10 (55.6) | 27 (61.4) | 14 (45.2) | |
| Tumour characteristics | ||||
| T2 | 1 (5.6) | 3 (6.8) | 4 (12.9) | 0.86 |
| T3 | 6 (33.3) | 24 (54.5) | 17 (54.8) | |
| T4 | 6 (33.3) | 14 (31.8) | 10 (32.3) | |
| N0 | 7 (38.9) | 15 (34.1) | 11 (35.5) | 0.89 |
| N1 | 3 (16.7) | 14 (31.8) | 10 (32.3) | |
| N2 | 5 (27.8) | 12 (27.3) | 10 (32.3) | |
| Locations of distant metastasis | ||||
| 1 | 8 (44.4) | 17 (38.6) | 10 (32.3) | 0.64 |
| 2 | 7 (38.9) | 23 (52.3) | 15 (48.4) | |
| ≥3 | 3 (16.7) | 4 (9.1) | 6 (19.4) | |
| Prior therapy | ||||
| Primary resection | 12 (66.7) | 27 (61.4) | 23 (74.2) | 0.51 |
| Adjuvant therapy | 6 (33.3) | 13 (29.5) | 13 (41.9) | 0.54 |
| folfiri as 1st-line therapy | 15 (83.3) | 36 (81.8) | 22 (71.0) | 0.48 |
| Bevacizumab use | 11 (61.1) | 17 (38.6) | 15 (48.4) | 0.26 |
| Outcome at study end | ||||
| Progressed | 11 (61.1) | 33 (75.0) | 22 (71.0) | 0.50 |
| Died before progression | 3 (16.7) | 8 (18.2) | 4 (12.9) | |
| Alive or lost to follow-up | 4 (22.2) | 3 (6.8) | 5 (16.1) | |
g-csf = granulocyte colony–stimulating factor; cci = Charlson comorbidity index; ecog = Eastern Cooperative Oncology Group; folfiri = irinotecan, 5-flourouracil, leucovorin.